| Entry |
|
|---|
| Name |
Cabergoline (JP18/USP/INN);
Cabaser (TN);
Dostinex (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C26H37N5O2
|
|---|
| Exact mass |
451.2947
|
|---|
| Mol weight |
451.60
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01472 Dopamine agonist
DG01468 Dopamine D2-receptor agonist
DG01964 Ergot alkaloid
DG01967 Antiparkinson agent
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 1169 |
|
|---|
| Efficacy |
Antiparkinsonian, Antidyskinetic, Dopamine D2 receptor agonist, Prolactin inhibitor |
|---|
| Disease |
Hyperprolactinemic [DS: H01388] |
|---|
| Comment |
Ergot alkaloid derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Network |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G02 OTHER GYNECOLOGICALS
G02C OTHER GYNECOLOGICALS
G02CB Prolactine inhibitors
G02CB03 Cabergoline
D00987 Cabergoline (JP18/USP/INN) <JP/US>
N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS
N04B DOPAMINERGIC AGENTS
N04BC Dopamine agonists
N04BC06 Cabergoline
D00987 Cabergoline (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Hormonal Agents, Suppressant (Pituitary)
Cabergoline
D00987 Cabergoline (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
116 Antiparkinsonian agents
1169 Others
D00987 Cabergoline (JP18/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01472 Dopamine agonist
DG01468 Dopamine D2-receptor agonist
D00987 Cabergoline
DG01964 Ergot alkaloid
D00987 Cabergoline
DG01967 Antiparkinson agent
D00987 Cabergoline
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00987 Cabergoline
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01967 Antiparkinson agent
D00987 Cabergoline
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D00987 Cabergoline (JP18/USP/INN) <JP/US>
Cytokines and receptors
Cytokines
CSF and other factors
PRL
D00987 Cabergoline (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00987 Cabergoline
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00987
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 33
1 C1y C 16.1698 -12.6119
2 C8y C 14.9855 -13.3060
3 C1y C 17.3599 -13.3003
4 C1x C 16.1698 -11.2350
5 C8y C 14.9855 -14.6829
6 C8x C 13.7895 -12.6176
7 N1y N 18.5501 -12.6119
8 C1x C 17.3658 -14.6771
9 C1y C 17.3599 -10.5524
10 C8y C 16.1698 -15.3656
11 C8y C 13.7895 -15.3656
12 C8x C 12.6052 -13.3060
13 C1x C 18.5501 -11.2350
14 C1b C 19.7344 -13.2944
15 C5a C 17.3482 -9.1755
16 C8x C 16.1698 -16.7424
17 N4x N 13.7895 -16.7424
18 C8x C 12.5993 -14.6829
19 C2b C 20.9245 -12.6059
20 N1c N 18.5384 -8.4871
21 O5a O 16.1581 -8.4871
22 C2a C 22.1088 -13.2886
23 C5a C 18.5325 -7.1104
24 C1b C 19.7227 -9.1698
25 N1b N 19.7168 -6.4277
26 O5a O 17.3365 -6.4277
27 C1b C 20.9187 -8.4813
28 C1b C 20.9070 -7.1045
29 C1b C 22.1030 -9.1640
30 C1a C 22.0913 -6.4220
31 N1c N 23.2931 -8.4756
32 C1a C 24.4774 -9.1581
33 C1a C 23.9698 -7.2796
BOND 36
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 2
5 2 6 1
6 3 7 1
7 3 8 1
8 4 9 1
9 5 10 1
10 5 11 1
11 6 12 2
12 7 13 1
13 7 14 1
14 9 15 1 #Up
15 10 16 2
16 11 17 1
17 11 18 2
18 14 19 1
19 15 20 1
20 15 21 2
21 19 22 2
22 20 23 1
23 20 24 1
24 23 25 1
25 23 26 2
26 24 27 1
27 25 28 1
28 27 29 1
29 28 30 1
30 29 31 1
31 31 32 1
32 31 33 1
33 8 10 1
34 9 13 1
35 12 18 1
36 16 17 1
|
|---|
